Parallabs is a newly formed corporation providing value added, technology driven bio-instruments to the life science research market
From its headquarters in Boston, USA, Parallabs will manufacture and market its own products to the US and Asian markets.
A European subsidiary with sales offices in the UK and Germany will market Parallabs's own products and complementary products from niche manufacturers.
In May 2005 Parallabs acquired the assets and rights to manufacture the Parallab 350, an integrated processing and automation system that greatly reduces the cycle time and reagents required for cycle sequencing, PCR, SNP, genotyping and diagnostic reactions.
Simultaneously Parallabs introduced a new concept in microarray printing.
The TopSpot E is a low cost personal microarrayer utilising non-contact technology optimised for the fabrication of DNA and protein microarrays.
In Europe Parallabs will also partner with DNA based companies such as Hamilton Thorne, Autogen, and Innovadyne, positioning itself to offer consistent high quality sales, support and service throughout Europe.
The success of Parallabs will be based upon working closely with biomedical researchers providing them with systems and applications solutions that aid and accelerate the discovery process, automating procedures to improve the effectiveness of their work.
CEO Stan Klein Stan holds a BS in biology from the City University of New York and an MBA from the Lubin School of Business, Pace University.
His diverse business background, including management, sales, new company start-ups, knowledge of cutting edge technology and manufacturing, and success in initial public offerings, is uniquely paired with first-hand he founded Protedyne, supplying industrial automation to the laboratory environment.
He secured $1M dollar series A financing in February, 2001 and in October obtained $12M in Series B financing to grow operations and fund on going research projects pertinent to long-term growth.
European Director Phil Branston has over 30 years experience in the industry, beginning life in sales and rising through sales management, marketing and operations.
Between 1995 and 2005 he was managing director of Anachem, a specialist, value added distributor serving the life science and environmental marketplaces.
Employing 150 people with a turnover in excess of $50m, Anachem has a good balance of income from capital products, consumables and service.
